Table 1.
Demographics and MRI findings of MRI/TRUS fusion prostate biopsy.
| Variable | One-Stop Pathway |
Standard Pathway |
|
|---|---|---|---|
| Median (IQR) or n (%) | Median (IQR) or n (%) | p value | |
| N | 74 | 296 | - |
| Age, years | 66 (60–70) | 66 (61–71) | 0.59 |
| CCI score | 1 (0–2) | 2 (0–2) | 0.17 |
| PSA, ng/mL | 5.4 (2.8–7.8) | 5.1 (3.3–7.3) | 0.10 |
| PSA density, ng/mL2 | 0.1 (0.1–0.2) | 0.1 (0.1–0.2) | 0.26 |
| Family history of PCa | 16 (22) | 71 (24) | 0.76 |
| Suspicious DRE | 19 (26) | 66 (23) | 0.65 |
| Prostate biopsy history | |||
| Biopsy-naïve | 35 (47) | 141 (48) | 1.0 |
| Prior negative biopsy | 22 (30) | 86 (29) | 1.0 |
| Active Surveillance/restaging biopsy | 17 (23) | 69 (22) | 1.0 |
| Time between MRI and biopsy, days | 0 | 7 (3–19) | <0.01 |
| Home-hospital distance, km | 163 (58–237) | 31 (16–79) | <0.01 |
| MRI findings | |||
| Prostate volume, mL | 42 (27–62) | 53 (38–73) | <0.01 |
| PI-RADS 1–2 | 23 (31) | 84 (28) | |
| PI-RADS 3 | 36 (49) | 164 (55) | 0.67 |
| PI-RADS 4 | 8 (11) | 31 (11) | |
| PI-RADS 5 | 7 (9) | 17 (6) | |
| Total number of lesions | |||
| 1 lesion | 26 (51) | 112 (53) | |
| 2 Lesions | 21 (41) | 74 (35) | 0.56 |
| ≥ 3 Lesions | 4 (8) | 26 (12) |
CCI: Charlson comorbidity index; PCa, prostate cancer; DRE, digital rectal examination; MRI, magnetic resonance imaging; PI-RADS, Prostate Imaging and Reporting Data System; PSA, prostate-specific antigen.